Voyager Therapeutics, Inc. (VYGR) saw its loss widen to $14.67 million, or $0.57 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $7.28 million, or $0.67 a share.
Revenue during the quarter plunged 52.16 percent to $2.36 million from $4.94 million in the previous year period.
Operating loss for the quarter was $13.84 million, compared with an operating loss of $7.44 million in the previous year period.
"Voyager's exceptional performance and accomplishments during 2016 created strong momentum for the company for 2017 and beyond as we continue to focus our efforts on developing gene therapies for devastating diseases of the CNS," said Steven Paul, M.D., president and chief executive officer of Voyager Therapeutics.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]